From Proof of Principle to Therapeutic Discipline: Strategies to Improve the Benefit/Risk Profile of Amyloid-Targeting Treatments for Alzheimer's Disease. (PubMed, CNS Drugs) - Sep 16, 2026 - "Lecanemab and donanemab have both demonstrated statistically robust and clinically meaningful, albeit still modest, slowing of disease progression, thereby establishing disease modification as a realistic therapeutic objective rather than a speculative aspiration. Real-world registries will be essential to define long-term safety, effectiveness, and treatment patterns outside clinical trial populations. Therefore, future improvement of amyloid-targeting treatments is likely to come from widening the therapeutic margin by drug engineering as well as precision implementation in real-world settings."
Benefit-risk assessment • Journal • Alzheimer's Disease • CNS Disorders • APOE
|
|
; Agnes Flöel; Anna Hofmann; Anna Hufnagel; Frank Jessen; Johannes Levin; Lutz Froelich; Oliver Peters; Robert Perneczky; Timo Grimmer
|